Stock AnalizNewAmsterdam Pharma Co N.V. NAMS
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
NewAmsterdam Pharma Co N.V. (NAMS) is a healthcare company listed in the US with a market value of about $2.4B. In the twelve months to September 30, 2026 it had revenue of $26M and net income of -$205M, a net margin of -789.9%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -25%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $26M | $23M | $46M | $14M | $103M | — | — |
| Net income | -$205M | -$204M | -$242M | -$177M | -$23M | -$42M | -$7M |
| Free cash flow | -$151M | -$148M | -$159M | -$141M | $10M | -$30M | -$7M |
| EPS (diluted) | $-1.68 | $-1.70 | $-2.01 | $-1.48 | $-0.19 | $-0.35 | $-0.06 |
| Net margin | -789.9% | -905.7% | -530.2% | -1255.8% | -22.0% | — | — |
| ROIC | — | -26.1% | -23.3% | -50.1% | -0.7% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $49.85, 147% above the current price; targets range from $37.71 to $59.54; the consensus rating is “Strong buy”; expected EPS is $-1.33 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does NewAmsterdam Pharma Co pay a dividend?
Not currently.
Is NewAmsterdam Pharma Co a good stock to buy?
We do not give buy or sell advice. NewAmsterdam Pharma Co scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.